For the first time in decades, people with advanced bladder cancer have more effective treatment options. New clinical trial results mark a key moment following years of little progress, bladder cancer experts believe.
Tarlatamab, a new type of targeted immunotherapy, shrank small cell lung cancer tumors in more than 30% of people taking part in an early-stage clinical trial. Those in the trial had small cell lung cancer that had gotten worse after treatments with other drugs.
A new study shows that, in some tumors, a subset of cancer cells can remove mitochondria—the tiny structures within cells that produce energy—from T cells to use for their own energy needs.
The Food and Drug Administration has approved fruquintinib (Fruzaqla) for colorectal cancer that has spread. It is used in adults who have already received treatment with certain cancer medicines.
